Robitussin (dextromethorphan and guaifenesin) and Mucinex ... Robitussin ER (Extended Release) 12-hour Cough Relief Robitussin Maximum Strength Robitussin Cough + Chest Congestion ...

The company had earlier received final approval from the United States Food and Drug Administration (USFDA) to market Mirabegron Extended-Release Tablets USP 25 mg and 50 mg (USRLD: Myrbetriq ...

Use Robitussin Cough + Chest Congestion DM Maximum Strength (Oral) exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than ...

Shares of Lupin rose nearly 4 percent after the pharmaceutical major announced the launch of Mirabegron Extended-Release tablets (25 mg) in the United States, a drug which has over $1 billion in ...

AHMEDABAD, India, April 22, 2024--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") announces the ...

The company had earlier received final approval from the United States Food and Drug Administration (USFDA) to market Mirabegron Extended-Release Tablets USP 25 mg and 50 mg (USRLD: Myrbetriq ...

The Mumbai-based drug maker has introduced the medication after receiving an approval from the US Food and Drug Administration (USFDA), Lupin said in a statement. The company's product is a generic ...

Lupin Limited announced the launch of the United States Food and Drug Administration (FDA) approved mirabegron extended-release tablets, 25 mg in US markets. Mirabegron extended-release tablets, 25 mg ...

The company has launched Mirabegron extended-release tablets in strength of 25 mg in the US market after having ... had annual sales of USD 2.42 billion in the US. Zydus shares were trading 2.9 per ...

Mirabegron extended-release tablets 25 mg and 50 mg had a market value of $2.42 billion, per IQVIA February 2024 data.